Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/9/22 Cytokinetics (CYTK) Omecamtiv Mecarbil (Oral) for Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) Subscribers Only Subscribers Only Subscribers Only
12/7/22 Esperion Therapeutics (ESPR) Nexletol for Dyslipidemia / Hypercholesterolemia Subscribers Only Subscribers Only Subscribers Only
12/6/22 Idorsia (IDIA) NBI-827104 for Partial Seizures (Epilepsy) Subscribers Only Subscribers Only Subscribers Only
12/6/22 Gossamer Bio (GOSS) GB002 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH) Subscribers Only Subscribers Only Subscribers Only
12/6/22 Editas (EDIT) EDIT-301 for Sickle Cell Anemia Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
12/08/22 Subscribers Only Subscribers Only Trial Data - Updated Results
12/08/22 Subscribers Only Subscribers Only Trial Data - Top-Line Results
12/08/22 Subscribers Only Subscribers Only Trial Data - Updated Results
12/08/22 Subscribers Only Subscribers Only Trial Data - Updated Results
12/08/22 Subscribers Only Subscribers Only Trial Data - Updated Results
Back to the top Back to the top